2024-11-02 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the development and commercialization of innovative therapies for serious diseases.

**Performance vs. S&P 500 (VOO):**
- **Cumulative Return (VRTX):** 176.19%
- **Cumulative Return (VOO):** 131.38%
- **Difference:** 44.81%
- **Relative Outperformance:** 77.42% (This means that VRTX's performance is in the 77.42% percentile relative to its historical performance compared to the S&P 500)

**Recent Price Movements:**
- **Last Closing Price:** 475.98
- **5-day Moving Average:** 475.1
- **20-day Moving Average:** 474.86
- **60-day Moving Average:** 474.49

**Technical Indicators:**
- **RSI:** 45.75 (Neutral)
- **PPO:** -0.09 (Slight Negative Momentum)
- **Delta_Previous_Relative_Divergence:** 7.55 (+) (Short-term Upward Trend)
- **Expected Return:** 5.88% (Expected long-term outperformance over S&P 500)

**Recent Earnings & Outlook:**
- **Earnings Per Share (EPS) and Revenue:**
    | Date       | EPS      | Revenue |
    |------------|----------|---------|
    | 2024-08-02 | -13.92  | 2.65 B$ |
    | 2024-05-07 | 4.26    | 2.69 B$ |
    | 2023-11-07 | 4.01    | 2.48 B$ |
    | 2023-08-02 | 3.55    | 2.49 B$ |
    | 2023-05-03 | 3.55    | 2.49 B$ |
- **Most recent earnings:**  The most recent earnings report (2024-08-02) showed an EPS of -13.92, which was below analysts' expectations. However, revenue exceeded expectations, demonstrating a strong demand for Vertex's products. 

**Financial Information:**
- **Revenue and Profitability:**
    | Quarter     | Revenue  | Profit Margin |
    |-------------|----------|--------------|
    | 2024-06-30 | $2.65B  | 85.94%       |
    | 2024-03-31 | $2.69B  | 87.27%       |
    | 2023-12-31 | $2.52B  | 85.38%       |
    | 2023-09-30 | $2.48B  | 87.17%       |
    | 2023-06-30 | $2.49B  | 87.62%       |
- **Capital and Profitability:**
    | Quarter     | Equity   | ROE     |
    |-------------|----------|---------|
    | 2024-06-30 | $14.77B | -24.32% |
    | 2024-03-31 | $18.55B | 5.93%   |
    | 2023-12-31 | $17.58B | 5.51%   |
    | 2023-09-30 | $16.51B | 6.27%   |
    | 2023-06-30 | $15.47B | 5.92%   |

**Recent News & Issues:**
- **Earnings Release:** Vertex reported its Q2 2024 earnings on August 2nd, 2024. While EPS fell short of expectations, the revenue exceeded forecasts, indicating strong demand for its products.
- **Market Outlook:** Vertex Pharmaceuticals remains a leading player in the cystic fibrosis market, with several new therapies in its pipeline. Analysts expect continued growth and innovation in the coming years.
- **Analyst Opinions:** Vertex has received mostly "Buy" and "Outperform" ratings from analysts. They are optimistic about the company's future prospects, citing its strong pipeline, market dominance in cystic fibrosis, and potential for expansion into other disease areas.

**Overall Analysis:**
Vertex Pharmaceuticals Inc. (VRTX) demonstrates strong performance, outperforming the S&P 500 by a significant margin. Its technical indicators point to a positive short-term trend with a healthy expected long-term return. Despite a recent miss on EPS, revenue continues to grow, reflecting healthy market demand. Analysts remain optimistic about Vertex's future prospects, with strong growth anticipated in the coming years. This makes VRTX a potentially attractive investment for investors seeking long-term growth and exposure to the biotechnology sector. 
